Combinations are the Future in FLT3-Mutated AML

EP. 1: Overview of FLT3-mutated AML

March 31st 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).

EP. 2: Prognostic Impact of FLT3 Mutations in AML

March 31st 2021

Insight regarding the assessment of the prevalence of FLT3-ITD versus FLT3-TKD mutations and allelic burden in newly diagnosed acute myeloid leukemia.

EP. 3: Testing for FLT3 During Relapse in AML

April 7th 2021

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

EP. 4: Using Second-Generation FLT3 Inhibitors in R/R AML

April 7th 2021

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

EP. 5: Optimizing Use of FLT3 Inhibitors in AML

April 14th 2021

Experts in leukemia comment on the utilization of FLT3 inhibitors in combination with chemotherapy in early and recurrent acute myeloid leukemia.

EP. 6: Phase 3 QuANTUM-R Study in R/R AML

April 14th 2021

Naval G. Daver, MD, reviews the safety and efficacy of quizartinib in relapsed/refractory acute myeloid leukemia as seen in the phase 3 QuANTUM-R study.

EP. 7: Importance of Achieving CR in AML

April 21st 2021

Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.

EP. 8: Combination Sorafenib Plus HMA in R/R AML

April 21st 2021

Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.

EP. 9: Developing Resistance With FLT3 Inhibitors in AML

April 28th 2021

Jessica K. Altman, MD, and Naval G. Daver, MD, discuss what is known in terms of mechanisms of resistance to FLT3 inhibitors used to treat acute myeloid leukemia.

EP. 10: Treatment Combinations in FLT3-Mutated AML

April 28th 2021

Experts in hematology comment on when it’s appropriate to use gilteritinib, particularly as a combination therapy, to treat patients with FLT3-mutated acute myeloid leukemia.